Eventide Asset Management
AXSM icon

Eventide Asset Management’s Axsome Therapeutics AXSM Stock Holding History

Eventide Asset Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$55.3M Sell
300,102
-16,718
-5% -$3.64M 0.78% 38
2026
Q2 		$77.5M Sell
316,820
-202,738
-39% -$44M 1.04% 27
2026
Q1 		$87.8M Sell
519,558
-51,668
-9% -$8.92M 1.45% 14
2025
Q4 		$104M Sell
571,226
-175,172
-23% -$24.5M 1.63% 10
2025
Q3 		$90.6M Buy
746,398
+20,726
+3% +$2.33M 1.49% 14
2025
Q2 		$75.7M Sell
725,672
-19,178
-3% -$2.03M 1.33% 17
2025
Q1 		$86.9M Sell
744,850
-83,861
-10% -$9.6M 1.73% 9
2024
Q4 		$70.1M Buy
828,711
+824
+0.1% +$75.8K 1.28% 23
2024
Q3 		$74.4M Sell
827,887
-110,827
-12% -$9.7M 1.28% 22
2024
Q2 		$75.6M Buy
938,714
+592,002
+171% +$43.8M 1.29% 23
2024
Q1 		$27.7M Hold
346,712
– – 0.43% 71
2023
Q4 		$27.6M Hold
346,712
– – 0.45% 67
2023
Q3 		$24.2M Buy
+346,712
New +$25.9M 0.44% 68

Other funds holding AXSM

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 42.55% 1-Year Est. Return
Alethea Capital Management
Alethea Capital Management Mercer Island, Washington $197M AUM 51.86% 1-Year Est. Return

Eventide Asset Management's AXSM Position: Q3 2026 in Review

Eventide Asset Management reduced its Axsome Therapeutics (AXSM) stake by 5.3% in Q3 2026, selling an estimated $3.64M and leaving 300,102 shares worth $55.3M. The position accounts for 0.78% of the portfolio, ranked #38.

Eventide Asset Management first reported a position in AXSM in Q3 2023 and has held it in 13 quarters since. The position peaked at $104M in Q4 2025. 348 funds tracked by Wall St. Rank hold AXSM as of Q3 2026.

  • Eventide Asset Management held 300,102 shares of Axsome Therapeutics worth $55.3M as of Q3 2026.
  • Eventide Asset Management sold 16,718 Axsome Therapeutics shares in Q3 2026, an estimated $3.64M.
  • Axsome Therapeutics made up 0.78% of Eventide Asset Management's portfolio in Q3 2026, its #38 holding.
  • Eventide Asset Management first reported a position in Axsome Therapeutics in Q3 2023 and has held it in 13 quarters since.
  • Eventide Asset Management's Axsome Therapeutics position peaked at $104M in Q4 2025.
  • 348 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2026.

Based on Eventide Asset Management's 13F filing for Q3 2026, filed 13 Nov 2026.